Literature DB >> 7689446

Mechanisms of resistance to quinolones.

E Cambau1, L Gutmann.   

Abstract

Mechanisms of resistance to the quinolones have been described for several bacterial species, but mainly for Escherichia coli and Staphylococcus aureus. Two principal mechanisms have been described: 1) alteration of the DNA gyrase, which is the target site of the quinolones; and 2) diminished accumulation in the cell as a result of either decreased uptake or increased efflux. Alteration of DNA gyrase is usually the result of a mutation in the gyrA, or more rarely, the gyrB gene. All substitutions in subunit A of the gyrase are located in the 67 to 106 amino-acid domain and are clustered around Ser-83 in E. coli and Ser-84 in S. aureus. A decrease in uptake has been described for Gram-negative bacteria such as Enterobacteriaceae and Pseudomonas aeruginosa. It has almost always been correlated with a modified electrophoretic profile of outer membrane proteins of the quinolone-resistant mutants. In E. coli, a decrease in OmpF seemed to be linked to the activation of the micF operon in most of the mutants described. These mutants were cross-resistant to unrelated antibiotics, such as trimethoprim, chloramphenicol, tetracycline, and some beta-lactams. In all these mutants the normal or enhanced efflux of quinolones increased the level of resistance. Enhanced efflux has been described as the second mechanism of resistance in S. aureus. Acquired resistance to the quinolones was thought, until recently, to result from chromosomal mutation. Plasmid-mediated resistance associated with an enhanced efflux has been described in S. aureus, but this needs to be confirmed. When a high level of resistance is observed, 2 or 3 mechanisms may be involved.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689446     DOI: 10.2165/00003495-199300453-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  72 in total

Review 1.  Active efflux mechanisms for antimicrobial resistance.

Authors:  S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  Mutation of Salmonella paratyphi A conferring cross-resistance to several groups of antibiotics by decreased permeability and loss of invasiveness.

Authors:  L Gutmann; D Billot-Klein; R Williamson; F W Goldstein; J Mounier; J F Acar; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

3.  Spontaneous quinolone resistance in Serratia marcescens due to a mutation in gyrA.

Authors:  B L Masecar; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

4.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

5.  Role of protein D2 and lipopolysaccharide in diffusion of quinolones through the outer membrane of Pseudomonas aeruginosa.

Authors:  M Michéa-Hamzehpour; Y X Furet; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

6.  The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein.

Authors:  A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

7.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

8.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

9.  Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB.

Authors:  D C Hooper; J S Wolfson; M A Bozza; E Y Ng
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.

Authors:  D C Hooper; J S Wolfson; K S Souza; E Y Ng; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  30 in total

1.  Induction of DnaK and GroEL heat shock proteins by fluoroquinolones in Escherichia coli.

Authors:  T Mizushima; M Matsuo; K Sekimizu
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

2.  Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations.

Authors:  H Wang; J L Dzink-Fox; M Chen; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 3.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 4.  Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

Authors:  S S Patel; C M Spencer
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Transrectal ultrasound guided prostate biopsy in the era of increasing fluoroquinolone resistance: prophylaxis with single-dose ertapenem.

Authors:  Michael Seitz; Christian Stief; Raphaela Waidelich; Markus Bader; Derya Tilki
Journal:  World J Urol       Date:  2017-05-03       Impact factor: 4.226

6.  Cloning and nucleotide sequence of the gyrA gene from Campylobacter fetus subsp. fetus ATCC 27374 and characterization of ciprofloxacin-resistant laboratory and clinical isolates.

Authors:  D E Taylor; A S Chau
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

7.  Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach.

Authors:  Adrien Fischer; Soo-Jin Yang; Arnold S Bayer; Ali R Vaezzadeh; Sébastien Herzig; Ludwig Stenz; Myriam Girard; George Sakoulas; Alexander Scherl; Michael R Yeaman; Richard A Proctor; Jacques Schrenzel; Patrice François
Journal:  J Antimicrob Chemother       Date:  2011-05-28       Impact factor: 5.790

Review 8.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

9.  Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors:  T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones.

Authors:  I Guillemin; E Cambau; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.